Appili Therapeutics
Halifax, CanadaIndustry
Appili Therapeutics develops anti-infectives for biodefence threats. CBRNE-relevant work is a minor part of its offering according to its website. It is headquartered in Halifax, Canada.
What it does
Threats covered
Categories
Profile
Appili Therapeutics is a Halifax infectious disease biotechnology company developing ATI-1701, a live-attenuated tularemia vaccine. Its US Air Force Academy and Defense Threat Reduction Agency cooperative agreement was extended through 31 August 2026, with about 11.7 million US dollars allotted and no further funding expected, which leaves a Food and Drug Administration investigational new drug application unfunded.
More profile
The company left the Toronto Stock Exchange on 2 October 2026 after failing continued listing requirements and began trading on the TSX Venture Exchange's NEX board as APLI.H on 5 October 2026. Its fiscal 2026 results were published in June 2026.
The founding year was not found. The company's other programmes were not read.
Ownership
Publicly listed; moved from the TSX to the TSX Venture NEX board as APLI.H on 5 October 2026
Parent: none (Aditxt arrangement terminated 30 May 2025) (checked)
Sources (5)
- https://appilitherapeutics.com/2026/06/26/appili-therapeutics-reports-fiscal-year-2026-financial-and-operational-results/
- https://appilitherapeutics.com/wp-content/uploads/2026/02/2512-Appili-December-31-2025-MDA-260212-FINAL.pdf
- https://www.biospace.com/press-releases/appili-therapeutics-announces-transfer-to-nex
- http://apps.tmx.com/TSXVenture/TSXVentureHttpController?GetPage=NoticesContents&NOTICE_ID=321408&PO_ID=1189381
- https://www.newsfilecorp.com/company/7197/Appili-Therapeutics-Inc.
Not verified or not found
- Founding year: not found.
- Other programmes and any antibiotic work: not read.
- Future of ATI-1701 without funding: not stated.
Questions
What does Appili Therapeutics do?
Appili Therapeutics develops anti-infectives for biodefence threats. CBRNE-relevant work is a minor part of its offering according to its website.
Where is Appili Therapeutics based?
HQ (as found): Halifax. HQ country: CA.
Who owns Appili Therapeutics?
Publicly listed; moved from the TSX to the TSX Venture NEX board as APLI.H on 5 October 2026. Parent: none (Aditxt arrangement terminated 30 May 2025) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction